ETF Exchange > THNR ETF
THNR - ETF Fact Sheet
Amplify Weight Loss Drug & Treatment ETF - USD
Fund Identification
Ticker
THNR
ISIN
US0321085328
Main Metrics
Price
$25.69Expense Ratio
0.59%AuM
$5.14MTracking Difference
1.54%Ratings
Trackinsight rating
N/AOfficial Investment Strategy
The Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index (the “Index”).
THNR's historical prices, performance, and flows
1m returns
5.95%
1m flows
$1M
* Net total returns
All data as of 17 July 2026
The ETF Exchange is brought to you by
With data and analysis by
See all THNR data with a
free P&I Online account
free P&I Online account
Enjoy unlimited ETF searches and access to tear-sheets of over 4,000 North-American funds.
or Login
THNR's characteristics
Manager
Manager statistics
43 funds, $19.29Bn in AUM
Benchmark
VettaFi Weight Loss Drug & Treatment Index - USD
Replication method
Direct (Physical)
Asset class
Equity
Dividend policy
Distributing
THNR's exposure
Countries
USA
52.50%
Denmark
16.52%
China
10.22%
Japan
9.53%
Other
11.22%
Sectors
Healthcare
100.00%
Top 5 holdings
Novo Nordisk A/S
14.39%
Eli Lilly & Co.
13.48%
Arrowhead Pharmaceuticals, Inc.
6.19%
Amgen, Inc.
6.02%
Regeneron Pharmaceuticals, Inc.
5.60%
Total holdings
20
Total weight of top 5
45.68%
